SCHEMBL3008048

SCHEMBL3008048

COc1ccc(S(=O)(=O)C2CCN(c3nc(-c4ccc(Cl)c(Cl)c4)cs3)CC2)cc1OC

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 14/20 0.53
RAB9A P51151 12/20 0.53
NPC1 O15118 10/20 0.53
MAPT P10636 5/20 0.53
AR P10275 1/20 0.51
L3MBTL1 Q9Y468 3/20 0.45
RECQL P46063 2/20 0.45
KDM4E B2RXH2 1/20 0.45
NTSR1 P30989 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
USP2 O75604 1/20 0.45
HSD17B10 Q99714 1/20 0.45
THRB P10828 1/20 0.42
ALDH1A1 P00352 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3008873 0.96 SMN1; SMN2 (0.56) SMN1; SMN2RAB9ANPC1MAPTAR
SCHEMBL3014772 0.93 SMN1; SMN2 (0.62) SMN1; SMN2RAB9ANPC1MAPTL3MBTL1
SCHEMBL3022821 0.92 SMN1; SMN2 (0.51) SMN1; SMN2RAB9ANPC1MAPTAR
SCHEMBL3021149 0.92 SMN1; SMN2 (0.51) SMN1; SMN2RAB9ANPC1MAPTAR
SCHEMBL3015049 0.91 SMN1; SMN2 (0.53) SMN1; SMN2RAB9ANPC1MAPTL3MBTL1
SCHEMBL3012500 0.90 SMN1; SMN2 (0.51) SMN1; SMN2RAB9ANPC1MAPTAR
SCHEMBL3007949 0.90 AR (0.60) SMN1; SMN2RAB9ANPC1MAPTAR
SCHEMBL3016651 0.89 SMN1; SMN2 (0.58) SMN1; SMN2RAB9ANPC1MAPTL3MBTL1
SCHEMBL3008106 0.89 SMN1; SMN2 (0.54) SMN1; SMN2RAB9ANPC1MAPTAR
SCHEMBL3001728 0.89 SMN1; SMN2 (0.53) SMN1; SMN2RAB9ANPC1MAPTAR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885RAB9A 2943/4885NPC1 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.